Evaluation of the dual peroxisome proliferator–activated receptor α/γ agonist aleglitazar to reduce...
Evaluation of the dual peroxisome proliferator–activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial
About this item
Full title
Author / Creator
Lincoff, A. Michael, MD , Tardif, Jean-Claude, MD , Neal, Bruce, PhD , Nicholls, Stephen J., MBBS, PhD , Rydén, Lars, MD , Schwartz, Gregory G., MD, PhD , Malmberg, Klas, MD , Buse, John B., MD, PhD , Henry, Robert R., MD , Wedel, Hans, PhD , Weichert, Arlette, MD , Cannata, Ruth, RN and Grobbee, Diederick E., MD, PhD
Publisher
United States: Mosby, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: Mosby, Inc
Subjects
More information
Scope and Contents
Contents
Background Peroxisome proliferator–activated receptors (PPARs) regulate transcription of genes involved in glucose uptake, lipid metabolism, and inflammation. Aleglitazar is a potent dual PPAR agonist with insulin-sensitizing and glucose-lowering actions and favorable effects on lipid profiles and biomarkers of cardiovascular risk. The AleCardio tr...
Alternative Titles
Full title
Evaluation of the dual peroxisome proliferator–activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_swepub_ki_se_527062
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_527062
Other Identifiers
ISSN
0002-8703
E-ISSN
1097-6744
DOI
10.1016/j.ahj.2013.05.013
